Inceptionr LLC Increases Position in Guardant Health, Inc. $GH

Posted by Geri Gentry on Jul 24th, 2026

Inceptionr LLC lifted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 89.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,762 shares of the company’s stock after buying an additional 6,029 shares during the quarter. Inceptionr LLC’s holdings in Guardant Health were worth $1,179,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in GH. Vanguard Group Inc. grew its holdings in shares of Guardant Health by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after buying an additional 435,232 shares during the last quarter. Geode Capital Management LLC increased its position in Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after buying an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in shares of Guardant Health by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after buying an additional 72,162 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Myrtle S. Potter sold 1,556 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $131.16, for a total value of $204,084.96. Following the sale, the director owned 20,971 shares of the company’s stock, valued at $2,750,556.36. This represents a 6.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 143,028 shares of Guardant Health stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the transaction, the chief executive officer owned 1,881,336 shares of the company’s stock, valued at $285,097,657.44. This represents a 7.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 708,565 shares of company stock worth $90,556,597 in the last 90 days. Insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

GH has been the topic of several analyst reports. Guggenheim lifted their target price on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Mizuho upped their price objective on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. UBS Group set a $150.00 target price on shares of Guardant Health in a research note on Wednesday, June 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Friday, July 17th. Finally, Morgan Stanley lifted their price objective on Guardant Health from $130.00 to $175.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $160.04.

View Our Latest Stock Report on GH

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $150.20 on Friday. The firm has a market capitalization of $19.92 billion, a price-to-earnings ratio of -44.31 and a beta of 1.59. The business’s 50 day simple moving average is $138.36 and its 200-day simple moving average is $111.70. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $174.08.

Guardant Health Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.